287 related articles for article (PubMed ID: 33221464)
1. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors.
Yeung J; Vender R; Turchin I; Shukla R; Maari C; Hong CH; Barakat M; Lansang P
J Am Acad Dermatol; 2021 Apr; 84(4):1169-1171. PubMed ID: 33221464
[No Abstract] [Full Text] [Related]
2. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
[No Abstract] [Full Text] [Related]
3. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
4. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
Kimura R; Sugita K; Yamamoto O
Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
[No Abstract] [Full Text] [Related]
5. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
Gasslitter I; Kirsten N; Augustin M; Torz K; Mrowietz U; Eyerich K; Puig L; Hoetzenecker W; Schütz-Bergmayr M; Weger W; Wolf P; Reider N; Ratzinger G; Papageorgiou K; Meier TO; Maul JT; Anzengruber F; Navarini AA
Arch Dermatol Res; 2019 Jul; 311(5):421-424. PubMed ID: 30879102
[TBL] [Abstract][Full Text] [Related]
6. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study.
Papp K; Prajapati VH; Maari C; Legault M; Barakat M; Vender R
J Am Acad Dermatol; 2024 Jun; 90(6):1254-1256. PubMed ID: 38290619
[No Abstract] [Full Text] [Related]
8. Use of anti-IL 17A for psoriasis is not necessarily contraindicated in organ transplantation patients.
Di Altobrando A; Lacava R; Patrizi A; Sacchelli L; La Manna G; Comai G; Bardazzi F
Eur J Dermatol; 2020 Jun; 30(3):311-313. PubMed ID: 32540794
[No Abstract] [Full Text] [Related]
9. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
10. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
11. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
12. Recapture Rate of Brodalumab in Patients With a Lapse in Treatment.
Lebwohl M; Cather J; Armstrong A; Van Voorhees A; Jacobson A
J Drugs Dermatol; 2020 Apr; 19(4):384-387. PubMed ID: 32272515
[TBL] [Abstract][Full Text] [Related]
13. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
Megna M; Cinelli E; Balato A; Gallo L; Fabbrocini G
J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e152-e153. PubMed ID: 31715054
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
17. Ixekizumab for the treatment of psoriasis: up-to-date.
Craig S; Warren RB
Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
[No Abstract] [Full Text] [Related]
18. Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors.
Oiwa T; Honda T; Otsuka A; Kabashima K
J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):e122-e123. PubMed ID: 28983980
[No Abstract] [Full Text] [Related]
19. Review of IL-17 inhibitors for psoriasis.
Amin M; Darji K; No DJ; Bhutani T; Wu JJ
J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
[No Abstract] [Full Text] [Related]
20. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.
Wilsmann-Theis D; Schnell LM; Ralser-Isselstein V; Bieber T; Schön MP; Hüffmeier U; Mössner R
J Dermatol; 2018 Jul; 45(7):850-854. PubMed ID: 29655177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
